"alpha-Glucosidases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enzymes that catalyze the exohydrolysis of 1,4-alpha-glucosidic linkages with release of alpha-glucose. Deficiency of alpha-1,4-glucosidase may cause GLYCOGEN STORAGE DISEASE TYPE II.
| Descriptor ID |
D000520
|
| MeSH Number(s) |
D08.811.277.450.420.050
|
| Concept/Terms |
alpha-Glucosidases- alpha-Glucosidases
- alpha Glucosidases
- Maltases
- alpha-Glucosidase
- alpha Glucosidase
- Maltase-Glucoamylase
- Maltase Glucoamylase
|
Below are MeSH descriptors whose meaning is more general than "alpha-Glucosidases".
Below are MeSH descriptors whose meaning is more specific than "alpha-Glucosidases".
This graph shows the total number of publications written about "alpha-Glucosidases" by people in this website by year, and whether "alpha-Glucosidases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 7 | 3 | 10 |
| 2019 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "alpha-Glucosidases" by people in Profiles.
-
The impact of interrupting enzyme replacement therapy in late-onset Pompe disease. J Neurol. 2021 Aug; 268(8):2943-2950.
-
a-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19. Biochem Soc Trans. 2020 Jun 30; 48(3):1287-1295.
-
Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. Rev Neurol (Paris). 2020 Jun; 176(6):507-515.
-
Biscoumarin-1,2,3-triazole hybrids as novel anti-diabetic agents: Design, synthesis, in vitro a-glucosidase inhibition, kinetic, and docking studies. Bioorg Chem. 2019 11; 92:103206.
-
Anti-diabetic treatment leads to changes in gut microbiome. Front Biosci (Landmark Ed). 2019 03 01; 24(4):688-699.
-
Pyrano[3,2-c]quinoline Derivatives as New Class of a-glucosidase Inhibitors to Treat Type 2 Diabetes: Synthesis, in vitro Biological Evaluation and Kinetic Study. Med Chem. 2019; 15(1):8-16.
-
Design and synthesis of novel quinazolinone-1,2,3-triazole hybrids as new anti-diabetic agents: In vitro a-glucosidase inhibition, kinetic, and docking study. Bioorg Chem. 2019 03; 83:161-169.
-
Novel thymol bearing oxypropanolamine derivatives as potent some metabolic enzyme inhibitors - Their antidiabetic, anticholinergic and antibacterial potentials. Bioorg Chem. 2018 12; 81:119-126.
-
Interaction of antidiabetic a-glucosidase inhibitors and gut bacteria a-glucosidase. Protein Sci. 2018 08; 27(8):1498-1508.
-
Design, synthesis, docking study, a-glucosidase inhibition, and cytotoxic activities of acridine linked to thioacetamides as novel agents in treatment of type 2 diabetes. Bioorg Chem. 2018 10; 80:288-295.